<DOC>
	<DOCNO>NCT02920047</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety administrate Fimasartan/Amlodipine co-administrated Fimasartan Amlodipine .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Pharmacokinetics Safety Fimasartan Amlodipine Healthy Male Subjects</brief_title>
	<detailed_description>This open-label , randomize , 3x3 partial replicate crossover study evaluate pharmacokinectics safety/tolerability . Within period , randomized subject 2 dose regimen fix dose combination Fimasartan/Amlodipine co-administration Fimasartan Amlodipine .</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Male 1950 year age . 2 . Body mass index ( BMI ) ≥ 18 ≤ 27 kg/m2 screening . 3 . Medically healthy clinically significant medical history . 4 . Understands study procedure Informed consent form ( ICF ) , willing able comply protocol . 1 . History presence clinically significant medical psychiatric condition disease . 2 . Positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) . 3 . Seated blood pressure le 100/65 mmHg great 140/90 mmHg screening . 4 . Plasma donation within month prior first dose study drug . 5 . Participation another clinical trial within 3 month prior first dose study drug ( ) .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Fimasartan</keyword>
</DOC>